Skip to main content
Equibles
OCEA logo

OCEA · Ocean Biomedical, Inc. · Metrics

Track OCEA — free

Use OCEA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCEA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 -0.01 (-52.20%) At close · Apr 24
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These events and conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed May 15, 2025
Market Cap
$348,547
Shares
232.37M
Volume · Apr 24 64.85M Avg daily vol (3M) 63.22M

OCEA metrics

47 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.01
Market cap
$348,547

Price action

20 metrics
Price change (1W)
-76.4%
Price change (30D)
—
Price change (3M)
-97.8%
Price change (6M)
-99.0%
Price change (YTD)
-98.2%
Price change (1Y)
-99.3%
Trailing year
Price change (5Y)
—
52-week high
$1.76
52-week low
$0.01
Change from 52-week high
-99.4%
Change from 52-week low
+0.0%
Annualized volatility
142.4%
Annualized volatility (3M)
225.4%
Beta
—
RSI (14D)
21.0
Price vs SMA 50
-86.9%
Price vs SMA 200
-98.5%
Avg volume (3M)
63.22M
Relative volume
1.0
Average dollar volume
$7.18M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
232.37M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8,813.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$4.16M
Net income (TTM)
−$30.72M
Trailing 12 months
Diluted EPS (TTM)
$-0.91
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.13
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.91
Operating cash flow per diluted share (TTM)
$-0.14
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.66

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
-163.4%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-118.8%
Shares change YoY
+232.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1,941.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$800,000
Total assets
$1.58M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.05M
Capital expenditures (TTM)
—
R&D (TTM)
$18,000
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.0%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1869974 CUSIP 67644C104 13F (30d) 1 filings 1 filers Visit website